Community physicians’ attitudes towards meetings with representatives of pharmaceutical companies: a pilot study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2052-3211
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Community physicians’ attitudes towards meetings with representatives of pharmaceutical companies: a pilot study ; volume:16 ; number:1 ; day:25 ; month:1 ; year:2023 ; pages:1-8 ; date:12.2023
Journal of pharmaceutical policy and practice ; 16, Heft 1 (25.1.2023), 1-8, 12.2023
- Creator
-
Koplovitz, Amit
Freud, Tamar
Peleg, Roni
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40545-023-00521-8
- URN
-
urn:nbn:de:101:1-2023040309385910805361
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Koplovitz, Amit
- Freud, Tamar
- Peleg, Roni
- SpringerLink (Online service)
Other Objects (12)
Interaction and medical inducement between pharmaceutical representatives and physicians: a meta-synthesis
Meetings of the House of Representatives
Regulating pharmaceutical companies’ financial largesse
Representatives
Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia
The effect of pharmaceutical companies’ marketing mix strategies on physicians prescribing practices in Jordan: a cross-sectional study
Grand Representatives
Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation
Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
Voters and Representatives: How Should Representatives Be Selected?
Changing R&D models in research-based pharmaceutical companies
Strategic Patenting by Pharmaceutical Companies – Should Competition Law Intervene?
Interaction and medical inducement between pharmaceutical representatives and physicians: a meta-synthesis
Meetings of the House of Representatives
Regulating pharmaceutical companies’ financial largesse
Representatives
Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia
The effect of pharmaceutical companies’ marketing mix strategies on physicians prescribing practices in Jordan: a cross-sectional study
Grand Representatives
Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation
Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
Voters and Representatives: How Should Representatives Be Selected?
Changing R&D models in research-based pharmaceutical companies
Strategic Patenting by Pharmaceutical Companies – Should Competition Law Intervene?
Interaction and medical inducement between pharmaceutical representatives and physicians: a meta-synthesis
Meetings of the House of Representatives
Regulating pharmaceutical companies’ financial largesse
Representatives
Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia
The effect of pharmaceutical companies’ marketing mix strategies on physicians prescribing practices in Jordan: a cross-sectional study
Grand Representatives
Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation
Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
Voters and Representatives: How Should Representatives Be Selected?
Changing R&D models in research-based pharmaceutical companies